Related Experiment Videos
Anaemia of prematurity. Epidemiology, management and costs
1Special Care Baby Unit, Middlemore Hospital, Auckland, New Zealand. mmeyer@ww.co.nz
Insights
Recombinant human erythropoietin (rHuEpo) reduces blood transfusions in preterm infants. While costly, targeted rHuEpo therapy can be cost-effective, especially for ill infants, and lowers infection risks.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pediatric Hematology
Background:
- Recombinant human erythropoietin (rHuEpo) is increasingly utilized in preterm infants.
- Studies suggest rHuEpo reduces the need for blood transfusions in this population.
- Potential adverse effects include iron deficiency if iron supplementation is insufficient.
Purpose of the Study:
- To evaluate the efficacy and cost-effectiveness of rHuEpo in preterm infants.
- To identify specific infant populations most likely to benefit from rHuEpo therapy.
- To assess the impact of rHuEpo on transfusion requirements and associated costs.
Main Methods:
- Review of recent studies on rHuEpo use in preterm infants.
- Analysis of cost data comparing rHuEpo therapy with blood transfusions.
- Examination of adverse event profiles associated with rHuEpo administration.
Main Results:
- rHuEpo significantly decreases blood transfusion requirements in preterm infants.
- Targeted rHuEpo therapy in stable growing preterm infants showed similar direct costs to transfusions, with a recommendation for its use.
- High-dose rHuEpo initiated early in neonatal intensive care units (NICUs) reduced direct treatment costs in critically ill preterm infants.
- Reduced risk of transfusion-related infections observed with rHuEpo use.
Conclusions:
- rHuEpo is a viable option for reducing blood transfusions in preterm infants.
- Careful patient selection and targeted therapy are crucial for optimizing rHuEpo cost-effectiveness.
- Further research is needed to refine patient selection criteria and fully define the economic benefits of rHuEpo in neonatal care.
Abstract:
Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is inadequate), and the risk of transfusion-related infection is decreased. Nevertheless, rHuEpo is relatively expensive (a 6-week course costs approximately the same as 2 blood transfusions), so its use requires careful consideration; it is logical to target rHuEpo therapy to those babies who are most likely to be transfused. Using this strategy, 1 study involving stable growing preterm infants has shown that direct costs of blood transfusion and rHuEpo were similar, and the use of rHuEpo was recommended. In addition, use of high-dosage rHuEpo early in the course of management on the neonatal intensive care unit has been shown to reduce direct treatment costs in ill preterm infants. Further studies will continue to identify infants who are likely to benefit from rHuEpo therapy and to define its cost effectiveness in more detail.